Graybug Vision, Inc. (NASDAQ:GRAY – Get Free Report)’s stock price fell 75.6% on Thursday . The company traded as low as $0.82 and last traded at $1.25. 44,974,361 shares traded hands during mid-day trading, an increase of 2,077,238% from the average session volume of 2,165 shares. The stock had previously closed at $5.12.
Graybug Vision Stock Down 11.8%
The firm has a market capitalization of $1.41 million, a P/E ratio of -0.52 and a beta of 1.20. The business’s 50-day simple moving average is $5.04 and its 200 day simple moving average is $3.76.
Graybug Vision Company Profile
Graybug Vision, Inc is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for retinal diseases. The company’s proprietary Depot Technology Platform is designed to deliver sustained-release formulations of biologically active agents directly to the back of the eye, with the goal of reducing treatment burden and improving patient outcomes. Graybug’s lead product candidate, GB-102, is a long-acting formulation of sunitinib malate being investigated for the treatment of wet age-related macular degeneration (wet AMD).
Further Reading
- Five stocks we like better than Graybug Vision
- Do not delete, read immediately
- NEW LAW: Congress Approves Setup For Digital Dollar?
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- A U.S. “birthright” claim worth trillions – activated quietly
- The Crash Has Already Started (Most Just Don’t See It Yet)
Receive News & Ratings for Graybug Vision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graybug Vision and related companies with MarketBeat.com's FREE daily email newsletter.
